Publikationen, an denen er mitarbeitet Ramón García Sanz (24)

2024

  1. A research center’s experience of T-cell–redirecting therapies in triple-class refractory multiple myeloma

    Blood Advances, Vol. 8, Núm. 13, pp. 3478-3487

  2. Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease

    British Journal of Haematology, Vol. 205, Núm. 1, pp. 109-121

2023

  1. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

    Cancers, Vol. 15, Núm. 5

2022

  1. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients

    Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067

  2. CT-195 Predictive Value of ST2, REG3a, and MAGIC Algorithm in Haploidentical Transplantation With Post-Transplant Cyclophosphamide Outcomes

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S438

  3. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205

2021

  1. Genetic complexity impacts the clinical outcome of follicular lymphoma patients

    Blood Cancer Journal

  2. Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping

    British Journal of Haematology, Vol. 195, Núm. 4, pp. 542-551

2019

  1. Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma

    Hematological Oncology

  2. Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas

    Blood Cancer Journal, Vol. 9, Núm. 7

2016

  1. Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse

    Oncotarget, Vol. 7, Núm. 49, pp. 80664-80679

  2. Lymphoma Heterogeneity: Three Different Histological Pictures and One Unique Clone

    CASE REPORTS IN HEMATOLOGY, Vol. 2016

2014

  1. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

    Leukemia, Vol. 28, Núm. 2, pp. 384-390

  2. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies

    Haematologica, Vol. 99, Núm. 8, pp. 1365-1372

2012

  1. Genomic analysis of high-risk smoldering multiple myeloma

    Haematologica, Vol. 97, Núm. 9, pp. 1439-1443

  2. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status

    Leukemia, Vol. 26, Núm. 12, pp. 2521-2529

2011

  1. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells

    Clinical Cancer Research, Vol. 17, Núm. 7, pp. 1692-1700

2010

  1. Aplicaciones del test sérico de cadenas ligeras libres en las gammapatías monoclonales

    Medicina Clinica, Vol. 135, Núm. 8, pp. 368-374

2000

  1. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

    Hematology Journal, Vol. 1, Núm. 1, pp. 28-36

1999

  1. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients

    Haematologica, Vol. 84, Núm. 3, pp. 231-236